This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Murphy Analytics Initiates Research Coverage On Tibet Pharmaceuticals

SHANGRI-LA COUNTY, China, April 19, 2011 /PRNewswire/ -- Tibet Pharmaceuticals, Inc. (NASDAQ: TBET), an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, today announced the release of an in-depth initiation report by Patrick Murphy, CFA, principal of fee-based, third-party research firm Murphy Analytics.

In his report, Mr. Murphy discusses Tibet Pharmaceuticals, its current portfolio of five traditional Tibetan medicine products, and initiates coverage with a 12-month price target of $11.00 per share.

"Tibet Pharmaceuticals is addressing the increasing demand for pharmaceutical and healthcare products in China, through our growing sales initiatives and portfolio of five SFDA-approved medicines," said Taylor Guo, Chief Executive Officer of Tibet Pharmaceuticals. "This comprehensive report provides investors with an excellent overview of Tibet Pharmaceuticals' unique strengths: from our strong research and development capabilities, our access to abundant raw materials not generally available outside the Tibetan geographical region and our significant potential for expansion based on our mission to grow both organically and through accretive acquisitions in 2011."

From the Murphy Analytics Research Report, Mr. Murphy states:

"Declared a 'national strategic industry' in the PRC, traditional Chinese medicine ('TCM') enjoys governmental support and is considered mainstream medicine in China, accounting for 21% of all medicine sold domestically. Although it represents a small percentage of the overall TCM market currently, traditional Tibetan medicine is growing at an estimated 50% per year, according to one estimate."

The report details the significant growth projected in China's traditional Tibetan medicine market, which benefits from rising individual wealth, an aging population, and PRC policy combined with domestic market forces that are expected to increase consumer spending on healthcare in China to $600 billion by 2015, a 3-fold increase over 2000.  Murphy Analytics also explains how Tibet Pharmaceuticals is attempting to translate this growth into future results, even at what Murphy Analytics considers conservative growth projections.

"Murphy Analytics estimates that the Company will deliver $14.3 million in income from operations, assuming only 10% revenue growth, which seems conservative relative to historical results," explains Mr. Murphy. "Given the conservative growth assumption and the additional $0.24 per share in expected tax savings for TBET for 2011, Murphy Analytics is initiating coverage on TBET with an $11.00 twelve-month price target."

The complete report is available in Acrobat format, free of charge:

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs